In contrast, IBD patients, many of whom receive anti-tumor necrosis factor (TNF) or other biologic therapies, appeared to benefit from attenuated myocardial inflammation, a phenomenon supported by studies showing that anti‐TNF agents reduce cardiac inflammatory infiltrates and improve ventricular function in experimental myocarditis, thereby translating into fewer heart failure events despite longer hospital stays for close monitoring or treatment optimization. This evidence concerns the gene TNF and inflammatory bowel disease.